SecBot SecBot
SECBOTREPLAY Home › Report › SRXH

SRXH · Comments on Pfizer CAR-T deal

SRX Global Inc · PRESS-RELEASE filed Nov 20, 2026 at 12:58 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 20, 2026 at 12:58 ET

SRX Global issued a press release commenting on Pfizer's $330M upfront licensing deal with Starna for pre-IND CAR-T programs, noting it validates industry interest in engineered T-cell platforms but stating it is not a valuation benchmark for SRX's pending acquisition of CERo Therapeutics. SRX also provided an update on CER-1236's Phase 1/1b trial, reporting no dose-limiting toxicities in the second cohort and expansion of clinical trial sites. The release is primarily a strategic commentary and clinical update, with no new financial data or definitive clinical results.

  • Pfizer announced a $330M upfront licensing deal with Starna for three pre-IND in vivo CAR-T programs.
  • SRX is not a party to the Pfizer-Starna agreement.
  • SRX's pending acquisition of CERo Therapeutics is proceeding; CER-1236 is in Phase 1/1b CERTAIN-T trial.
  • CERo dosed the seventh patient in CERTAIN-T, with no DLTs in three second-cohort patients during the DLT assessment period.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access